Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 2:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 13,929 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Trial Clear all

Conditions: Anterior Cruciate Ligament Injuries, Anterior Cruciate Ligament Rupture, Pain, Postoperative
Interventions: Tranexamic Acid, Placebo; Drug
Lead sponsor: Dave Bernholt; Other
Eligibility: 14 Years to 25 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 6
States / cities: Skokie, Illinois • St Louis, Missouri • Durham, North Carolina + 3 more

Conditions: Diabetic Neuropathy Peripheral
Interventions: Active Provant Therapy System, Inactive (sham) Provant Therapy System; Device
Lead sponsor: Regenesis Biomedical, Inc.; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 18
States / cities: Mesa, Arizona • Northridge, California • Sacramento, California + 15 more

Conditions: Noninfectious Uveitis
Interventions: Filgotinib, Placebo to match filgotinib, Prednisone; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 15
States / cities: Palo Alto, California • Golden, Colorado • Chicago, Illinois + 12 more

Conditions: PTSD
Interventions: Experimental, Active Control; Behavioral
Lead sponsor: Thomas Adams; Other
Eligibility: 21 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Human Immunodeficiency Virus
Interventions: HealthMindr Application, Waitlist; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 1,229 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Atlanta, Georgia • Detroit, Michigan • New York, New York

Conditions: Neonatal Abstinence Syndrome
Interventions: Human Milk, Standard of Care; Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: Up to 48 Hours
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Meningococcal Vaccine
Interventions: rLP2086, Havrix (HAV), Saline; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 3,596 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 62
States / cities: Birmingham, Alabama • Dothan, Alabama • Harrisburg, Arkansas + 42 more

Conditions: Depression - Major Depressive Disorder
Interventions: Approach-Avoidance Decision-Making Task; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: COPD Exacerbation
Interventions: Intervention; Behavioral
Lead sponsor: Albert Einstein Healthcare Network; Other
Eligibility: 55 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ischemic Foot Ulcer
Interventions: Endovascular Revascularization; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 110 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypertension, Cardiovascular Diseases
Interventions: Mixture of Sodium Nitrite and N-acetylcysteine (NAC) crytals.; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 21 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Stress, Professional, Stress, Psychological
Interventions: Mindfulness-based self care; Behavioral
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cardiovascular Diseases, Personal Health Records, Pharmaceutical Care, Mobile Apps
Interventions: Pharmacist-led cardiovascular risk service (CVRS), Mobile access to study Personal Health Record, Web access to study Personal Health Record; Other
Lead sponsor: University of Iowa; Other
Eligibility: 55 Years to 99 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Iowa City, Iowa • Sioux City, Iowa

Conditions: Breast Cancer
Interventions: Linear Aerobic Training, Nonlinear Aerobic Training, Progressive Stretching, Cardiopulmonary exercise test (CPET), Blood draws; Behavioral · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 45 Years to 80 Years · Female only
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Venous Leg Ulcers
Interventions: NuShield®; Other
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Pickerington, Ohio

Conditions: Type 2 Diabetes
Interventions: Extra Virgin Olive Oil, Refined Olive Oil; Other
Lead sponsor: Griffin Hospital; Other
Eligibility: 25 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Derby, Connecticut

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: VHB937, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 21
States / cities: La Jolla, California • Loma Linda, California • Los Angeles, California + 18 more

Conditions: Open Midline Laparotomy
Interventions: Phasix™ Mesh; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 18 Years and older
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2031
U.S. locations: 20
States / cities: Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 17 more

Conditions: Thyroid Eye Disease
Interventions: Celecoxib, artificial tears; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Lymphoblastic Leukemia, Transcranial Direct Current Stimulation, Executive Dysfunction
Interventions: Anodal tDCS treatment, Cathodal tDCS treatment, Sham treatment, NIH Toolbox List Sorting Working Memory Test, NIH Toolbox Flanker Inhibitory Control and Attention Test, Grooved Peg Board Test, Buschke Selective Reminding Test; Device · Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 8 Years to 215 Months
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Dry Eye Disease (DED)
Interventions: OC-01 (varenicline) nasal spray, Placebo (vehicle) nasal spray; Drug
Lead sponsor: Oyster Point Pharma, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 758 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 22
States / cities: Phoenix, Arizona • Newport Beach, California • Fort Collins, Colorado + 18 more

Conditions: Medical Adherence
Interventions: GlowCap, Daily email, text message, or phone call reminders, Paid for adherence; Device · Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 84 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Vascular Disease
Interventions: ArterX Surgical Sealant, Gelfoam and Thrombin; Device
Lead sponsor: Tenaxis Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Hepatitis C
Interventions: TMC435, Placebo, Peg-IFN-alfa-2a (P), Ribavirin (R); Drug
Lead sponsor: Tibotec Pharmaceuticals, Ireland; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 17
States / cities: La Jolla, California • Los Angeles, California • Jacksonville, Florida + 14 more

Search by objective public record fields.

Extended Post-Operative Oral Tranexamic Acid Dosing After ACL Reconstruction

Dual Field PEMF Therapy in Lower Extremity Painful Diabetic Distal Symmetric Peripheral Neuropathy

Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis

Exercise and Therapeutic Exposure

Mobile Messaging Intervention to Present New HIV Prevention Options for Men Who Have Sex With Men (MSM)

Clinical Trial to Decrease Length of Stay in Infants With Neonatal Abstinence Syndrome With an Exclusive Human Milk Diet

A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

Understanding the Neural Underpinnings of Risk-Taking Behavior in Psychiatric Disease

Health Literacy Activation RCT Among the COPD Patients and Designated Support Dyad

Ischemic Foot Ulcers: Is Intervention Better Than Wound Care Alone

Effect of Sublingually Generated S-nitroso-N-acetylcysteine on Systemic Blood Pressure.

Brief Mindfulness Meditation Course to Reduce Stress in Healthcare Professionals

Mobile Cardiovascular Risk Service Trial

Trial Comparing the Effects of Linear Versus Nonlinear Aerobic Training in Women With Operable Breast Cancer

Clinical Trial Evaluating NuShield® Plus Standard of Care (SOC) Versus Standard of Care (SOC) Alone in the Management of Non-Healing Venous Leg Ulcers (VLUs)

Post-prandial Effects of Extra Virgin Olive Oil on Endothelial Function in Adults at Risk for Type 2 Diabetes

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

Prophylactic Reinforcement of Ventral Abdominal Incisions Trial

Celecoxib for Thyroid Eye Disease

Transcranial Direct Current Stimulation of the Temporal Cortex in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL)

Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

GlowCaps Adherence Randomized Control Trial

ArterX Surgical Sealant, A Randomized Prospective Multicenter Trial

A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment